Skip to main content
Top
Published in: Pathology & Oncology Research 1/2012

01-01-2012 | Research

HLA-DRB1,-DQA1 and -DQB1 Allele and Haplotype Frequencies in Female Patients with Early Onset Breast Cancer

Authors: Majid Mahmoodi, Hedayat Nahvi, Mahdi Mahmoudi, Amir Kasaian, Mohammad-Ali Mohagheghi, Kouros Divsalar, Bijan Nahavandian, Abbas Jafari, Bita Ansarpour, Batoul Moradi, Asghar Aghamohammadi, Aliakbar Amirzargar

Published in: Pathology & Oncology Research | Issue 1/2012

Login to get access

Abstract

Based on the reports, few HLA class II alleles are associated with susceptibility or protection in breast cancer. Here we investigate the association between HLA class II alleles and breast cancer in Iranian women. 100 patients with pathologically proven breast cancer who referred to Cancer Institute were randomly selected and compared with a group of 80 healthy blood donor subjects. The patients were studied in two groups, group 1 includes patients aging 40 years or younger and group 2 include patients aging over 40 years. HLA class II alleles were determined by amplification of DNA followed by HLA-typing using sequence-specific primer (SSP) for each allele. In group 1, the most frequent alleles were HLA-DQA1*0301 (P = 0.002, OR = 3.3) and HLA-DQB1*0302 (P = 0.04, OR = 2.8). In group 2, the following alleles increased significantly than those in controls including HLA-DQA1*0301 (P = 0.001, OR = 3.4) and HLA-DRB1*0301 (P = 0.04, OR = 2.3). In complete group of patients, the frequency of HLA-DQA1*0301 (P = 0.001, OR = 3.4) and HLA-DRB1*1303 (P = 0.02, OR = 2.3) increased significantly than those in control group. HLA-DQA1*0505, HLA-DQA1*0101, HLA-DRB1*1301and HLA-DRB1*0101 alleles showed negative association with breast cancer. Our findings suggest that HLA-DQA1*0301 allele is mainly associated with increased risk of breast cancer including early-onset of the disease. HLA-DQA1*0505 and HLA-DRB1*1301 are involved in protection. We conclude that specific alleles of HLA class II influence breast cancer risk.
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRef Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRef
2.
go back to reference Forbes JF (1997) The incidence of breast cancer: the global burden, public health considerations. Semin Oncol 24(Suppl 1):S1-20–S1-35 Forbes JF (1997) The incidence of breast cancer: the global burden, public health considerations. Semin Oncol 24(Suppl 1):S1-20–S1-35
3.
go back to reference de Jong MM, Nolte IM, te Meerman GJ et al (2002) Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 39(4):225–242PubMedCrossRef de Jong MM, Nolte IM, te Meerman GJ et al (2002) Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 39(4):225–242PubMedCrossRef
4.
go back to reference Futreal PA, Liu Q, Shattuck-Eidens D et al (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 7(266(5182)):120–122CrossRef Futreal PA, Liu Q, Shattuck-Eidens D et al (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 7(266(5182)):120–122CrossRef
5.
go back to reference Pistillo MP, Nicolò G, Salvi S et al (2000) Biochemical analysis of HLA class I subunits expression in breast cancer tissues. Hum Immunol 61:397–407PubMedCrossRef Pistillo MP, Nicolò G, Salvi S et al (2000) Biochemical analysis of HLA class I subunits expression in breast cancer tissues. Hum Immunol 61:397–407PubMedCrossRef
6.
go back to reference Salih HR, Nussler V (2001) Commentary: immune escape versus tumor tolerance: how do tumors evade immune surveillance? Eur J Med Res 6:323–332PubMed Salih HR, Nussler V (2001) Commentary: immune escape versus tumor tolerance: how do tumors evade immune surveillance? Eur J Med Res 6:323–332PubMed
7.
go back to reference Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998PubMedCrossRef Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998PubMedCrossRef
8.
go back to reference Forbes SA, Trowsdale J (1997) The MHC quarterly report. Immunogenetics 50:152–159CrossRef Forbes SA, Trowsdale J (1997) The MHC quarterly report. Immunogenetics 50:152–159CrossRef
9.
go back to reference Hosono S, Kawase T, Matsuo K et al (2010) HLA-A alleles and the risk of cervical squamous cell carcinoma in Japanese women. J Epidemiol 20(4):295–301PubMedCrossRef Hosono S, Kawase T, Matsuo K et al (2010) HLA-A alleles and the risk of cervical squamous cell carcinoma in Japanese women. J Epidemiol 20(4):295–301PubMedCrossRef
10.
go back to reference Castro FA, Haimila K, Sareneva I et al (2009) Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population–a candidate gene approach. Int J Cancer 125(8):1851–1858PubMedCrossRef Castro FA, Haimila K, Sareneva I et al (2009) Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population–a candidate gene approach. Int J Cancer 125(8):1851–1858PubMedCrossRef
11.
go back to reference Lee HW, Hahm KB, Lee JS et al (2009) Association of the human leukocyte antigen class II alleles with chronic atrophic gastritis and gastric carcinoma in Koreans. J Dig Dis 10(4):265–271PubMedCrossRef Lee HW, Hahm KB, Lee JS et al (2009) Association of the human leukocyte antigen class II alleles with chronic atrophic gastritis and gastric carcinoma in Koreans. J Dig Dis 10(4):265–271PubMedCrossRef
12.
go back to reference Ishigami S, Natsugoe S, Nakajo A et al (2008) HLA-class I expression in gastric cancer. J Surg Oncol 97(7):605–608PubMedCrossRef Ishigami S, Natsugoe S, Nakajo A et al (2008) HLA-class I expression in gastric cancer. J Surg Oncol 97(7):605–608PubMedCrossRef
13.
go back to reference Gamzatova Z, Villabona L, van der Zanden H et al (2007) Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer. Tissue Antigens 70(3):205–213PubMedCrossRef Gamzatova Z, Villabona L, van der Zanden H et al (2007) Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer. Tissue Antigens 70(3):205–213PubMedCrossRef
14.
go back to reference Gogas H, Kirkwood JM, Falk CS et al (2010) Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer 116(18):4326–4333PubMedCrossRef Gogas H, Kirkwood JM, Falk CS et al (2010) Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer 116(18):4326–4333PubMedCrossRef
15.
go back to reference Chaudhuri S, Cariappa A, Tang M et al (2000) Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci U S A 97(21):11451–11454PubMedCrossRef Chaudhuri S, Cariappa A, Tang M et al (2000) Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci U S A 97(21):11451–11454PubMedCrossRef
16.
go back to reference Ghaderi A, Talei A, Gharesi-Fard B et al (2001) HLA-DRB1 alleles and the susceptibility of Iranian patients with breast cancer. Pathol Oncol Res 7:39–41PubMedCrossRef Ghaderi A, Talei A, Gharesi-Fard B et al (2001) HLA-DRB1 alleles and the susceptibility of Iranian patients with breast cancer. Pathol Oncol Res 7:39–41PubMedCrossRef
17.
go back to reference Lavado R, Benavides M, Villar E et al (2005) The HLA-B7 allele confers susceptibility to breast cancer in Spanish women. Immunol Lett 101(2):223–225PubMedCrossRef Lavado R, Benavides M, Villar E et al (2005) The HLA-B7 allele confers susceptibility to breast cancer in Spanish women. Immunol Lett 101(2):223–225PubMedCrossRef
18.
go back to reference Cantú de León D, Pérez-Montiel D, Villavicencio V et al (2009) High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study. BMC Cancer 9:48PubMedCrossRef Cantú de León D, Pérez-Montiel D, Villavicencio V et al (2009) High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study. BMC Cancer 9:48PubMedCrossRef
19.
go back to reference Miller SA, Dykes DD, Polesky HE (1989) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215–1221CrossRef Miller SA, Dykes DD, Polesky HE (1989) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215–1221CrossRef
20.
go back to reference Amirzargar AA, Khosravi F, Dianat SS et al (2007) Association of HLA class II allele and haplotype frequencies with chronic myelogenous leukemia and age-at-onset of the disease. Pathol Oncol Res 13(1):47–51PubMedCrossRef Amirzargar AA, Khosravi F, Dianat SS et al (2007) Association of HLA class II allele and haplotype frequencies with chronic myelogenous leukemia and age-at-onset of the disease. Pathol Oncol Res 13(1):47–51PubMedCrossRef
21.
go back to reference Olerup O, Zetterquist H (1992) HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39:225–235PubMedCrossRef Olerup O, Zetterquist H (1992) HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39:225–235PubMedCrossRef
22.
go back to reference Amirzargar A, Mytilineos J, Farjadian S et al (2001) Human leukocyte antigen class II allele frequencies and haplotype association in Iranian normal population. Hum Immunol 62:1234–1238PubMedCrossRef Amirzargar A, Mytilineos J, Farjadian S et al (2001) Human leukocyte antigen class II allele frequencies and haplotype association in Iranian normal population. Hum Immunol 62:1234–1238PubMedCrossRef
23.
go back to reference McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast cancer–epidemiology, risk factors and genetics. BMJ 321(7261):624–628PubMedCrossRef McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast cancer–epidemiology, risk factors and genetics. BMJ 321(7261):624–628PubMedCrossRef
24.
go back to reference Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917PubMedCrossRef Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917PubMedCrossRef
26.
go back to reference Anderson BO, Jakesz R (2008) Breast cancer issues in developing countries: an overview of the Breast Health Global Initiative. World J Surg 32:2578–2585PubMedCrossRef Anderson BO, Jakesz R (2008) Breast cancer issues in developing countries: an overview of the Breast Health Global Initiative. World J Surg 32:2578–2585PubMedCrossRef
27.
go back to reference The Top 10 Causes of Death in 2004 (2008) Fact Sheet of WHO Report, World Health Organization. The Top 10 Causes of Death in 2004 (2008) Fact Sheet of WHO Report, World Health Organization.
28.
go back to reference Harirchi I, Mousavi SM, Mohagheghi MA et al (2009) Early detection for breast cancer in Iran. Asian Pac J Cancer Prev 10(5):849–851PubMed Harirchi I, Mousavi SM, Mohagheghi MA et al (2009) Early detection for breast cancer in Iran. Asian Pac J Cancer Prev 10(5):849–851PubMed
29.
go back to reference Mousavi SM, Gouya MM, Ramazani R et al (2009) Cancer incidence and mortality in Iran. Ann Oncol 20:556–563PubMedCrossRef Mousavi SM, Gouya MM, Ramazani R et al (2009) Cancer incidence and mortality in Iran. Ann Oncol 20:556–563PubMedCrossRef
30.
go back to reference Baccar Harrath A, Yacoubi Loueslati B, Troudi W et al (2006) HLA class II polymorphism: protective or risk factors to breast cancer in Tunisia? Pathol Oncol Res 12(2):79–81PubMedCrossRef Baccar Harrath A, Yacoubi Loueslati B, Troudi W et al (2006) HLA class II polymorphism: protective or risk factors to breast cancer in Tunisia? Pathol Oncol Res 12(2):79–81PubMedCrossRef
31.
go back to reference Ferrera A, Olivo A, Alaez C et al (1999) HLA-DOA1 and -DOB1 loci in Honduran women with cervical dysplasia and invasive cervical carcinoma and their relationship to human papillomavirus infection. Hum Biol 71(3):367–379PubMed Ferrera A, Olivo A, Alaez C et al (1999) HLA-DOA1 and -DOB1 loci in Honduran women with cervical dysplasia and invasive cervical carcinoma and their relationship to human papillomavirus infection. Hum Biol 71(3):367–379PubMed
Metadata
Title
HLA-DRB1,-DQA1 and -DQB1 Allele and Haplotype Frequencies in Female Patients with Early Onset Breast Cancer
Authors
Majid Mahmoodi
Hedayat Nahvi
Mahdi Mahmoudi
Amir Kasaian
Mohammad-Ali Mohagheghi
Kouros Divsalar
Bijan Nahavandian
Abbas Jafari
Bita Ansarpour
Batoul Moradi
Asghar Aghamohammadi
Aliakbar Amirzargar
Publication date
01-01-2012
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9415-6

Other articles of this Issue 1/2012

Pathology & Oncology Research 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine